BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » Takeda

Fujifilm and Takeda To Co-Develop Regenerative Therapies Using iPS Cell-Derived Cardiomyocytes

February 9, 2018 By Cade Hildreth (CEO) Leave a Comment

Fujifilm CDI Takeda

iPS Cell Therapies - CDI and FUJIFILMFUJIFILM Corporation and Takeda Pharmaceutical have announced they will partner to develop regenerative therapies using iPS cell-derived cardiomyocytes produced by Fujfilm’s subsidiary, Cellular Dynamics International (CDI).

As stated by Aiichiro Hiruma, General Manager of Regenerative Medicine Division at FUJIFILM Corporation:

Takeda“We are delighted to initiate this partnership applying practical use of our iPSC-derived cardiac cells with Takeda, which has abundant experience in drug development and clinical trials. In addition to establishing new treatment methods for patients with heart disease, Fujifilm and Takeda will contribute to the elevation of regenerative medication business to the industrial stage by applying our engineering technologies to manufacture high-quality cells safely and efficiently.”

At its core, the partnership will align manufacturing technology possessed by Cellular Dynamics International, an affiliate company of Fujifilm, with Takeda’s iPSC expertise and research to be conducted by the Center for iPS Cell Research and Application (CiRA) at Kyoto University. Together, these synergies will support pre-clinical and clinical studies for regenerative medicines that will address unmet cardiac needs, with a focus on heart failure.  [Read more…]

Filed Under: iPS Cells Tagged With: cardiac, CDI, FUJIFILM, Takeda

Nanocellect

Marathon Products

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram
Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Top Rated Products

  • Job Posting on BioInformant Job Posting on BioInformant.com - Your Perfect Hire Is In Our Audience
    Rated 0 out of 5
    $297
  • U.S. Cord Blood Banking Survey Cord Blood Banking Survey of U.S. Parents [2017]
    Rated 0 out of 5
    $197
  • Exosome Companies 2020 Global Database of Exosome Companies
    Rated 0 out of 5
    $149 $97
My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: Info@BioInformant.com | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.